• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:13:06 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DARE alert in real time by email
    SC 13G/A 1 d71292dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO 13d-2 (b)

    (Amendment No. 1)

     

     

    Daré Bioscience, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    23666P101

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Continued on following pages)


    CUSIP #23666P101

     

      1    

      NAME OF REPORTING PERSONS

     

      Polaris Venture Partners III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware    

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0    

       6   

      SHARED VOTING POWER

     

      1,142,961 (1)    

       7   

      SOLE DISPOSITIVE POWER

     

      0    

       8   

      SHARED DISPOSITIVE POWER

     

      1,142,961 (1)    

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,142,961 (1)    

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐    

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      2.4% (2)    

    12  

      TYPE OF REPORTING PERSON

     

      PN    

     

    (1)

    All such are held of record by PVP III (as defined in Item 2(a) below). PVM III (as defined in Item 2(a) below), the general partner of PVP III, may be deemed to have voting, investment and dispositive power with respect to these securities. Jonathan A. Flint and Terrance G. McGuire, the managing members of PVM III, may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,846,235 shares of Common Stock outstanding as reported on the Issuer’s Prospectus (File No. 333-251599) January 7, 2021 filed with the United States Securities and Exchange Commission pursuant to Rule 424(b)(3) on January 7, 2021 (the “Prospectus”).


    CUSIP #23666P101

     

      1    

      NAME OF REPORTING PERSONS

     

      Polaris Venture Partners Entrepreneurs’ Fund III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware    

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0    

       6   

      SHARED VOTING POWER

     

      29,152 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0    

       8   

      SHARED DISPOSITIVE POWER

     

      29,152 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      29,152 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐    

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0.1% (2)

    12  

      TYPE OF REPORTING PERSON

     

      PN    

     

    (1)

    All such are held of record by PVPE III (as defined in Item 2(a) below). PVM III, the general partner of PVPE III, may be deemed to have voting, investment and dispositive power with respect to these securities. Jonathan A. Flint and Terrance G. McGuire, the managing members of PVM III, may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,846,235 shares of Common Stock outstanding as reported by the Issuer in its Prospectus.


    CUSIP #23666P101

     

      1    

      NAME OF REPORTING PERSONS

     

      Polaris Venture Partners Founders’ Fund III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware    

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0    

       6   

      SHARED VOTING POWER

     

      17,760 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0    

       8   

      SHARED DISPOSITIVE POWER

     

      17,760 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,760 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐    

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0.0% (2)

    12  

      TYPE OF REPORTING PERSON

     

      PN    

     

    (1)

    All such are held of record by PVPFF III (as defined in Item 2(a) below). PVM III, the general partner of PVPFF III, may be deemed to have voting, investment and dispositive power with respect to these securities. Jonathan A. Flint and Terrance G. McGuire, the managing members of PVM III, may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,846,235 shares of Common Stock outstanding as reported by the Issuer in its Prospectus.


    CUSIP #23666P101

     

      1    

      NAME OF REPORTING PERSONS

     

      Polaris Venture Management Co. III, L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware    

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0    

       6   

      SHARED VOTING POWER

     

      1,189,873 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0    

       8   

      SHARED DISPOSITIVE POWER

     

      1,189,873 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,189,873 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐    

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      2.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      OO    

     

    (1)

    1,142,961 of such shares are held of record by PVP III, 29,152 of such shares are held of record by PVPE III, and 17,760 of such shares are held of record by PVPFF III. PVM III, the general partner of each of PVP III, PVPE III and PVPFF III, may be deemed to have voting, investment and dispositive power with respect to these securities. Jonathan A. Flint and Terrance G. McGuire, the managing members of PVM III, may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,846,235 shares of Common Stock outstanding as reported by the Issuer in its Prospectus.


    CUSIP #23666P101

     

      1    

      NAME OF REPORTING PERSONS

     

      Jonathan A. Flint

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0    

       6   

      SHARED VOTING POWER

     

      1,659,325 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0    

       8   

      SHARED DISPOSITIVE POWER

     

      1,659,325 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,659,325 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐    

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      3.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      IN    

     

    (1)

    1,142,961 of such shares are held of record by PVP III, 29,152 of such shares are held of record by PVPE III, and 17,760 of such shares are held of record by PVPFF III. PVM III, the general partner of each of PVP III, PVPE III and PVPFF III, may be deemed to have voting, investment and dispositive power with respect to these securities. Jonathan A. Flint (“Flint”) and Terrance G. McGuire (“McGuire”), the managing members of PVM III, may each be deemed to share voting, investment and dispositive power with respect to these securities. 140,574 of such shares are held of record by Polaris Venture Partners IV, L.P. (“PVP IV”) and 2,635 of such shares are held of record by Polaris Venture Partners Entrepreneurs’ Fund IV, L.P. (“PVPE IV”). Polaris Venture Management Co. IV, LLC (“PVM IV”) the general partner of each of PVP IV and PVPE IV may be deemed to have voting, investment and dispositive power with respect to these securities. Flint and McGuire, the managing members of PVM IV, may each be deemed to share voting, investment and dispositive power with respect to these securities. 314,803 of such shares are held of record by Polaris Venture Partners V, L.P. (“PVP V”), 6,135 of such shares are held of record by Polaris Partners Entrepreneurs’ Fund V, L.P. (“PVPE V”), 2,156 of such shares are held of record by Polaris Venture Partners Founders’ Fund V, L.P. (“PVPFF V”) and 3,147 of such shares are held of record by Polaris Venture Partners Special Founders’ Fund V, L.P. (“ PVPSFF V”). Polaris Venture Management Co. V, LLC (“ PVM V”), the general partner of each of PVP V, PVPE V, PVPFF V and PVPSFF V, may be deemed to have voting, investment and dispositive power with respect to these securities. Flint and McGuire, the managing members of PVM V, may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,846,235 shares of Common Stock outstanding as reported by the Issuer in its Prospectus.


    CUSIP #23666P101

     

      1    

      NAME OF REPORTING PERSONS

     

      Terrance G. McGuire

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      0    

       6   

      SHARED VOTING POWER

     

      1,659,325 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0    

       8   

      SHARED DISPOSITIVE POWER

     

      1,659,325 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,659,325 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐    

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      3.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      IN    

     

    (1)

    1,142,961 of such shares are held of record by PVP III, 29,152 of such shares are held of record by PVPE III, and 17,760 of such shares are held of record by PVPFF III. PVM III, the general partner of each of PVP III, PVPE III and PVPFF III, may be deemed to have voting, investment and dispositive power with respect to these securities. Flint and McGuire, the managing members of PVM III, may each be deemed to share voting, investment and dispositive power with respect to these securities. 140,574 of such shares are held of record by PVP IV and 2,635 of such shares are held of record by PVPE IV. PVM IV the general partner of each of PVP IV and PVPE IV may be deemed to have voting, investment and dispositive power with respect to these securities. Flint and McGuire, the managing members of PVM IV, may each be deemed to share voting, investment and dispositive power with respect to these securities. 314,803 of such shares are held of record by PVP V, 6,135 of such shares are held of record by PVPE V, 2,156 of such shares are held of record by PVPFF V and 3,147 of such shares are held of record by PVPSFF V. PVM V, the general partner of each of PVP V, PVPE V, PVPFF V and PVPSFF V, may be deemed to have voting, investment and dispositive power with respect to these securities. Flint and McGuire, the managing members of PVM V, may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,846,235 shares of Common Stock outstanding as reported by the Issuer in its Prospectus.


    CUSIP # 23666P101

     

    ITEM 2(A).

    NAME OF PERSONS FILING

    This Amendment No. 1 (“Amendment No.1”) amends and supplements the Schedule 13G initially filed with the United States Securities and Exchange Commission on February 12, 2020 (the “Original 13G”) by the Reporting Persons. The “Reporting Persons” are collectively, Polaris Venture Partners III, L.P. (“PVP III”), Polaris Venture Partners Entrepreneurs’ Fund III, L.P. (“PVPE III”), Polaris Venture Partners Founders’ Fund III, L.P. (“PVPFF III”), Polaris Venture Management Co. III, L.L.C. (“PVM III”), Jonathan A. Flint (“Flint”), and Terrance G. McGuire (“McGuire”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13G.

     

    ITEM 4.

    OWNERSHIP

    The following information with respect to the ownership of the common stock of the Issuer by the Reporting Persons filing this Statement is provided as of December 31, 2020:

    (a) Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person and the corresponding footnotes.*

    (b) Percent of Class:

    See Row 11 of cover page for each Reporting Person and the corresponding footnotes.*

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person and the corresponding footnotes.*

    (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his, her or its pecuniary interest therein.

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5% of the class of securities, check the following:  ☒


    CUSIP # 23666P101

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2021

     

    POLARIS VENTURE PARTNERS III, L.P.
    By:   Polaris Venture Management Co. III, L.L.C.
    By:  

    *

      Authorized Signatory
    POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND III, L.P.
    By:   Polaris Venture Management Co. III, L.L.C.
    By:  

    *

      Authorized Signatory
    POLARIS VENTURE PARTNERS FOUNDERS’ FUND III, L.P.
    By:   Polaris Venture Management Co. III, L.L.C.
    By:  

    *

      Authorized Signatory
    POLARIS VENTURE MANAGEMENT CO. III, L.L.C.
    By:  

    *

      Authorized Signatory
    JONATHAN A. FLINT
    By:  

    *

      Jonathan A. Flint
    TERRANCE G. MCGUIRE
    By:  

    *

      Terrance G. McGuire

     

    *By:  

    /s/ Lauren Crockett

    Name:   Lauren Crockett
      Attorney-in-Fact


    [This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $DARE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DARE

    DatePrice TargetRatingAnalyst
    6/30/2021$9.00 → $11.00Buy
    Roth Capital
    More analyst ratings

    $DARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chef Executive Officer Johnson Sabrina Martucci

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    2/20/26 4:01:50 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chef Executive Officer Johnson Sabrina Martucci

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    2/2/26 4:06:47 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Accounting Officer Haring-Layton Mardee

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    2/2/26 4:05:49 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules

    First Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the upcoming commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. The launch represents a milestone for Daré, as the company expects to generate its first direct consumer product revenue in June

    6/4/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

    Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trialDARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatmentsAward reflects Daré's strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contra

    5/26/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

    Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027 SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the initiation of its Phase 2 clinical study of DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, designed to evalu

    5/18/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    SEC Filings

    View All

    SEC Form DEFA14A filed by Dare Bioscience Inc.

    DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)

    6/1/26 5:14:59 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Dare Bioscience Inc.

    DEFA14A - Dare Bioscience, Inc. (0001401914) (Filer)

    6/1/26 8:59:59 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    5/18/26 4:25:47 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Dare Bioscience with a new price target

    Roth Capital reiterated coverage of Dare Bioscience with a rating of Buy and set a new price target of $11.00 from $9.00 previously

    6/30/21 9:55:24 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Leadership Updates

    Live Leadership Updates

    View All

    Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

    A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce

    7/29/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Announces Executive Team and Board of Directors Changes

    SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh

    1/26/24 4:30:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

    SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. "We are thrilled to add Dr. Ononye-Onyia to the Daré Board," said Sabrina Martucci Johnson, Daré's President and CEO. "Sophia has demonstrated the value of her leadership to global biopharmaceutical companies throughout her career. Her experience supporting commercialization of women's health products positions her to provide strategic guidance as our product candidates advance toward commercialization, and as we explore the variety of go-to-market partnering strategies

    4/19/21 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

    Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week. Conference Call and Webcast Today at 4:30 p.m. ET "We are hosting our financial results and business update call from New York, in the middle of National Women's Health Week," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. "Daré was built on the conviction that women's health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribb

    5/14/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

    SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2026, to review its financial results for the quarter ended March 31, 2026 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2531472. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at ht

    5/7/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:36 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:35 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/12/21 5:13:06 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care